Cancer Immunotherapies Attracting Interest
I’ve always been a bit skeptical of cancer immunotherapies, particularly the use of patients’ own immune system to target tumors. Just look at CancerVax, Cell Genesys, Favrille, and Genitope. One of...
View ArticleFDA Approval Rates
CDER NMEs CDER BLAs CBER BLAs Total 1999 35 2 3 40 2000 27 3 3 33 2001 24 6 2 32 2002 17 6 3 26 2003 21 6 8 35 2004 31 5 2 38 2005 18 2 8 28 2006 18 4 7 29 2007 16 2 8 26 2008 21 3 7 31 2009 19 6 9 34...
View ArticleHow To Read a Biotech Patent
Reading patents can be painful if you’re not a patent attorney. It can be hard enough to comprehend all the science without trying to understand the legal jargon. If you’re totally unfamiliar with...
View ArticlePortfolio Diversification: When Not to Diversify
Diversification is not always good. It’s common sense that having more shots on goal increases the probability of making a goal. Financial advisors will always recommend diversifying your investment...
View ArticleVC Financing Down for First Half of 2011
EvaluatePharma recently reported VC investments in companies developing human therapeutics (excluding diagnostics, devices, medical instruments, etc.). A total of $1.9 million was invested in 98 deals...
View ArticleKaplan-Meier Curves in Excel
Clinical studies often use Kaplan-Meier (aka survival) curves to show the proportion of patients that have survived after a certain period of time. There are a several articles that show you how to do...
View ArticleOption Pain Calculator in Excel
I’ve become somewhat interested in the Max (Option) Pain Theory recently. In short, it’s a way to predict the price of a stock on a certain date using open option interest. The theory, which has been...
View ArticleKaplan-Meier Curves with R
While Excel (and similar spreadsheet programs) are powerful, they are not really suited for survival analysis. For example, graphing Kaplan-Meier curves with Excel is less than ideal. Survival analysis...
View ArticleRemember Financing Risk When Investing in Microcap Biotech Stocks
Investing in publicly-traded, early-stage, microcap biotech stocks can be very profitable. For example, if you had invested in shares of Advaxis (ADXS) in 2014 which traded at less than $4 for most of...
View ArticleClik here to view.
An Example of Financing Risk in a Microcap Biotech Stock
I previously blogged about financing risks associated with microcap biotech companies. In this post, I wanted examine a real-life example of a microcap biotech that recently had to raise capital. On...
View Article
